IL264956B2 - Anti-pd1 monoclonal antibody, pharmaceutical preparation thereof and use thereof - Google Patents
Anti-pd1 monoclonal antibody, pharmaceutical preparation thereof and use thereofInfo
- Publication number
- IL264956B2 IL264956B2 IL264956A IL26495619A IL264956B2 IL 264956 B2 IL264956 B2 IL 264956B2 IL 264956 A IL264956 A IL 264956A IL 26495619 A IL26495619 A IL 26495619A IL 264956 B2 IL264956 B2 IL 264956B2
- Authority
- IL
- Israel
- Prior art keywords
- monoclonal antibody
- binding fragment
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7019—Ischaemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610705763.5A CN106977602B (zh) | 2016-08-23 | 2016-08-23 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| PCT/CN2017/098465 WO2018036472A1 (zh) | 2016-08-23 | 2017-08-22 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL264956A IL264956A (en) | 2022-12-01 |
| IL264956B2 true IL264956B2 (en) | 2023-04-01 |
Family
ID=59340342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264956A IL264956B2 (en) | 2016-08-23 | 2019-02-21 | Anti-pd1 monoclonal antibody, pharmaceutical preparation thereof and use thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12076398B2 (enExample) |
| EP (2) | EP4509186A3 (enExample) |
| JP (1) | JP7082620B2 (enExample) |
| KR (1) | KR102469286B1 (enExample) |
| CN (1) | CN106977602B (enExample) |
| AU (2) | AU2017316255C1 (enExample) |
| BR (1) | BR112019003775A2 (enExample) |
| EA (1) | EA201990570A1 (enExample) |
| ES (1) | ES3001154T3 (enExample) |
| FI (1) | FI3505535T3 (enExample) |
| HU (1) | HUE069593T2 (enExample) |
| IL (1) | IL264956B2 (enExample) |
| LT (1) | LT3505535T (enExample) |
| MX (1) | MX2019002268A (enExample) |
| NZ (1) | NZ751902A (enExample) |
| PL (1) | PL3505535T3 (enExample) |
| PT (1) | PT3505535T (enExample) |
| RS (1) | RS66372B1 (enExample) |
| SG (1) | SG11201901584UA (enExample) |
| SI (1) | SI3505535T1 (enExample) |
| WO (1) | WO2018036472A1 (enExample) |
| ZA (1) | ZA201901781B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| KR20250020679A (ko) | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| CN109425736B (zh) * | 2017-08-25 | 2021-04-09 | 北京百普赛斯生物科技股份有限公司 | 一种检测pd-1抗体血药浓度的方法及试剂盒 |
| KR20200059243A (ko) * | 2017-09-20 | 2020-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| WO2019195621A1 (en) * | 2018-04-04 | 2019-10-10 | Immutics, Inc. | Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides |
| EA202092136A1 (ru) | 2018-05-07 | 2021-03-22 | Генмаб А/С | Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства |
| JP7460608B2 (ja) | 2018-05-07 | 2024-04-02 | ジェンマブ エー／エス | 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
| CN116077647B (zh) * | 2018-07-18 | 2025-06-27 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| CN109053889B (zh) * | 2018-07-25 | 2019-06-21 | 博奥信生物技术（南京）有限公司 | 一种抗人pd1单克隆抗体及用途 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| PL3946377T3 (pl) | 2019-04-03 | 2026-04-20 | Orega Biotech | Terapie skojarzone oparte na inhibitorach pd1 i il-17b |
| CN110373415B (zh) * | 2019-06-12 | 2023-06-09 | 安徽省昂普拓迈生物科技有限责任公司 | 特异性结合pd-l1蛋白的核酸适配体及其用途 |
| JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| BR112022002028A2 (pt) | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| EP4008730A4 (en) * | 2019-08-02 | 2023-09-06 | Akeso Pharmaceuticals, Inc. | BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES |
| WO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
| CN110903391B (zh) * | 2019-10-25 | 2021-05-28 | 东大生物技术(苏州)有限公司 | 一组pd-l1单克隆抗体及其医药用途 |
| CN112915202B (zh) * | 2019-12-06 | 2025-08-01 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| EP4079763A4 (en) * | 2019-12-20 | 2023-10-11 | Guangdong Feipeng Pharmaceutical Co., Ltd | MONOCLONAL ANTIBODY AGAINST HUMAN PROGRAMMED DEATH-1 (PD-1) |
| CN113117072A (zh) * | 2020-01-14 | 2021-07-16 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| US20230045494A1 (en) | 2020-02-28 | 2023-02-09 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
| BR112022021426A2 (pt) * | 2020-04-22 | 2022-12-13 | Akeso Biopharma Inc | Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73 |
| KR20230003178A (ko) | 2020-04-29 | 2023-01-05 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | PD-1 및 TGF-β에 대한 이중 기능성 단백질 |
| CN113754767A (zh) * | 2020-06-03 | 2021-12-07 | 上海恒润达生生物科技股份有限公司 | 抗人pd-1抗体及其用途 |
| CN114761434B (zh) * | 2020-09-30 | 2023-06-27 | 苏州沙砾生物科技有限公司 | Pd-1抗体及其制备方法与应用 |
| CN114470191A (zh) * | 2020-10-27 | 2022-05-13 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| CN114470190A (zh) * | 2020-10-27 | 2022-05-13 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| CN114432438A (zh) * | 2020-11-04 | 2022-05-06 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| MX2023005528A (es) | 2020-11-17 | 2023-06-23 | Seagen Inc | Metodos de tratamiento del cancer con una combinacion de tucatinib y un anticuerpo anti-pd-1/anti-pd-l1. |
| CN113336848B (zh) * | 2021-02-03 | 2022-08-19 | 上海莱馥医疗科技有限公司 | 一种抗pd-1抗体及其用途 |
| EP4293046A4 (en) * | 2021-02-10 | 2025-03-05 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | Anti-pd-1 antibody and use thereof |
| AU2022233411A1 (en) * | 2021-03-12 | 2023-09-14 | Akeso Biopharma, Inc. | Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof |
| WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| EP4410835A4 (en) | 2021-09-29 | 2025-09-24 | Akeso Biopharma Inc | ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE |
| WO2023057534A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| CN113912710B (zh) * | 2021-11-17 | 2023-05-26 | 杭州旭科生物技术有限公司 | 抗新型冠状病毒n蛋白的单克隆抗体及其应用 |
| CN117069850B (zh) * | 2021-12-20 | 2025-02-14 | 南京诺唯赞检测技术有限公司 | 一种vce的单克隆抗体及其制备方法 |
| EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
| CN119031933B (zh) * | 2022-04-12 | 2025-08-26 | 正大天晴(广州)医药有限公司 | 蛋白酶体抑制剂与抗pd-1抗体的药物组合 |
| CA3253038A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY |
| EP4522654A1 (en) | 2022-05-12 | 2025-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| US20250282873A1 (en) | 2022-05-13 | 2025-09-11 | Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharmaceutical Group | Drug combination of anti-tim-3 antibody and anti-pd-1 antibody |
| CN119789867A (zh) * | 2022-09-06 | 2025-04-08 | 正大天晴药业集团股份有限公司 | 结合tim-3的抗体与结合pd-1的抗体的药物组合 |
| EP4598960A1 (en) * | 2022-10-05 | 2025-08-13 | Chulalongkorn University | Monoclonal antibodies against human programmed cell death protein 1 (pd-1) |
| CN117986356B (zh) * | 2022-10-27 | 2025-07-22 | 纽迈生物科技(苏州)有限公司 | 一种制备抗体的方法 |
| CN120302979A (zh) | 2022-12-01 | 2025-07-11 | 生物技术公司 | 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗 |
| EP4688160A1 (en) | 2023-04-06 | 2026-02-11 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| IL324457A (en) | 2023-05-12 | 2026-01-01 | Genmab As | Antibodies capable of binding to ox40, their variants and uses thereof |
| WO2025056014A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| WO2025056011A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| CN122249464A (zh) | 2023-11-30 | 2026-06-19 | 金麦安博股份有限公司 | 在组合疗法中的能够结合ox40的抗体 |
| CN118652343B (zh) * | 2024-07-08 | 2025-05-09 | 吉林省医菲尼迪生物医药有限公司 | 一种临床血液免疫细胞以及在治疗疾病中的应用 |
| KR20260116273A (ko) | 2024-09-20 | 2026-07-28 | 파라곤 테라퓨틱스, 인크. | Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105175544A (zh) * | 2015-10-20 | 2015-12-23 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) * | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| WO2010036959A2 (en) * | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| WO2011113019A2 (en) | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2012135408A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| CA2833636A1 (en) * | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| CN111499755A (zh) * | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| DK3049441T3 (da) | 2013-09-27 | 2020-02-03 | Hoffmann La Roche | Anti-PDL1-antistofformuleringer |
| CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN104974253A (zh) | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| CN104987421A (zh) | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| CN105175545B (zh) * | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| CN105754990A (zh) | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
-
2016
- 2016-08-23 CN CN201610705763.5A patent/CN106977602B/zh active Active
-
2017
- 2017-08-22 JP JP2019531512A patent/JP7082620B2/ja active Active
- 2017-08-22 EP EP24206755.1A patent/EP4509186A3/en active Pending
- 2017-08-22 EA EA201990570A patent/EA201990570A1/ru unknown
- 2017-08-22 LT LTEPPCT/CN2017/098465T patent/LT3505535T/lt unknown
- 2017-08-22 SI SI201731577T patent/SI3505535T1/sl unknown
- 2017-08-22 MX MX2019002268A patent/MX2019002268A/es unknown
- 2017-08-22 US US16/327,083 patent/US12076398B2/en active Active
- 2017-08-22 SG SG11201901584UA patent/SG11201901584UA/en unknown
- 2017-08-22 FI FIEP17842895.9T patent/FI3505535T3/fi active
- 2017-08-22 NZ NZ751902A patent/NZ751902A/en unknown
- 2017-08-22 BR BR112019003775-6A patent/BR112019003775A2/pt active Search and Examination
- 2017-08-22 AU AU2017316255A patent/AU2017316255C1/en active Active
- 2017-08-22 PT PT178428959T patent/PT3505535T/pt unknown
- 2017-08-22 WO PCT/CN2017/098465 patent/WO2018036472A1/zh not_active Ceased
- 2017-08-22 HU HUE17842895A patent/HUE069593T2/hu unknown
- 2017-08-22 ES ES17842895T patent/ES3001154T3/es active Active
- 2017-08-22 PL PL17842895.9T patent/PL3505535T3/pl unknown
- 2017-08-22 KR KR1020197008464A patent/KR102469286B1/ko active Active
- 2017-08-22 RS RS20250001A patent/RS66372B1/sr unknown
- 2017-08-22 EP EP17842895.9A patent/EP3505535B1/en active Active
-
2019
- 2019-02-21 IL IL264956A patent/IL264956B2/en unknown
- 2019-03-22 ZA ZA2019/01781A patent/ZA201901781B/en unknown
-
2024
- 2024-04-17 AU AU2024202527A patent/AU2024202527B2/en active Active
- 2024-07-22 US US18/780,086 patent/US20250041409A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105175544A (zh) * | 2015-10-20 | 2015-12-23 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
Non-Patent Citations (3)
| Title |
|---|
| ANONYMOUS, STUDY OF REGN2810 (ANTI-PD-1) IN PATIENTS WITH ADVANCED MALIGNANCIES - FULL TEXT VIEW - CLINICALTRIALS.GOV, 9 March 2015 (2015-03-09) * |
| BRAHMER ET AL.,, NIVOLUMAB: TARGETING PD-1 TO BOLSTER ANTITUMOR IMMUNITY,, 1 May 2015 (2015-05-01) * |
| MCDERMOTT ET AL.,, PEMBROLIZUMAB: PD-1 INHIBITION AS A THERAPEUTIC STRATEGY IN CANCER,, 1 January 2015 (2015-01-01) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3505535T3 (fi) | Anti-pd1 monoklonaalinen vasta-aine, sen farmaseuttinen koostumus ja sen käyttö | |
| JP2024522360A5 (enExample) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| FI3882275T3 (fi) | Bifunktionaalinen anti-PD-1- ja anti-VEGFA-vasta-aine, sen farmaseuttinen koostumus ja sen käyttö | |
| JP2020534830A5 (enExample) | ||
| CN112135626A (zh) | 抗tigit抗体及其用途 | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2022542165A5 (enExample) | ||
| JP2020501598A5 (enExample) | ||
| JP2018512170A5 (enExample) | ||
| JP2021516051A5 (enExample) | ||
| RU2019107134A (ru) | Анти-pd-1 антитела | |
| RU2010129423A (ru) | Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках, и способы их применения | |
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| IL273196B1 (en) | Claudin 6 antibodies and methods of cancer treatment | |
| JP2019534034A5 (enExample) | ||
| JP2019534892A5 (enExample) | ||
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2023546743A5 (enExample) | ||
| JP2010523096A5 (enExample) | ||
| CN116731182A (zh) | 靶向dll3的抗体、抗原结合片段及其用途 | |
| JP2022532173A5 (enExample) | ||
| RU2012126098A (ru) | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) |